SUBSCRIBE
SUBSCRIBE
News   Deals

GlaxoSmithKline Eyeing 51 Percent in India’s Shantha biotech: Report

May 29, 2009 | 
1 min read

Bookmark and Share

MUMBAI (Reuters) - British drug firm GlaxoSmithKline Plc is in talks to buy a 51 percent stake in India’s unlisted Shantha Biotech after prospective bidder Sanofi Aventis dropped out, the Economic Times said on Friday.

Mergers & acquisitions Asia
GlaxoSmithKline
MORE ON THIS TOPIC
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & acquisitions
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: AstraZeneca building in Gothenburg/iStoc
China
AstraZeneca Names New International Operations Lead Amid Probe on China Exec
December 5, 2024
 · 
3 min read
 · 
Tristan Manalac
Handshake gesture contemporary collage art. Celebrating success, congratulating for financial and business partnership, job contract deal, mutual friendship and respect. Abstract illustration isolated.
Alzheimer’s disease
GSK Strikes Third Agreement This Week, Leans Further Into Neuro
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac
GSK's headquarters office building in Poznan, Poland
ADCs
GSK Turns Back to China in Another Potential $1B+ ADC Deal
December 4, 2024
 · 
1 min read
 · 
Kate Goodwin